These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 11560871)
1. Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Kosuge K; Jun Y; Watanabe H; Kimura M; Nishimoto M; Ishizaki T; Ohashi K Drug Metab Dispos; 2001 Oct; 29(10):1284-9. PubMed ID: 11560871 [TBL] [Abstract][Full Text] [Related]
2. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Inomata S; Nagashima A; Itagaki F; Homma M; Nishimura M; Osaka Y; Okuyama K; Tanaka E; Nakamura T; Kohda Y; Naito S; Miyabe M; Toyooka H Clin Pharmacol Ther; 2005 Dec; 78(6):647-55. PubMed ID: 16338280 [TBL] [Abstract][Full Text] [Related]
3. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574 [TBL] [Abstract][Full Text] [Related]
4. Voriconazole and fluconazole increase the exposure to oral diazepam. Saari TI; Laine K; Bertilsson L; Neuvonen PJ; Olkkola KT Eur J Clin Pharmacol; 2007 Oct; 63(10):941-9. PubMed ID: 17676319 [TBL] [Abstract][Full Text] [Related]
5. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561 [TBL] [Abstract][Full Text] [Related]
6. The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects. Bramness JG; Skurtveit S; Gulliksen M; Breilid H; Steen VM; Mørland J Eur J Clin Pharmacol; 2005 Aug; 61(7):499-506. PubMed ID: 16021435 [TBL] [Abstract][Full Text] [Related]
7. Single-dose pharmacokinetics and pharmacodynamics of oral triazolam in relation to cytochrome P4502C19 (CYP2C19) activity. Yasui N; Otani K; Ohkubo T; Osanai T; Sugawara K; Chiba K; Ishizaki T; Kaneko S Ther Drug Monit; 1997 Aug; 19(4):371-4. PubMed ID: 9263374 [TBL] [Abstract][Full Text] [Related]
8. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Uno T; Sugimoto K; Sugawara K; Tateishi T Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598 [TBL] [Abstract][Full Text] [Related]
9. 5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity. Shu Y; Wang LS; Xu ZH; He N; Xiao WM; Wang W; Huang SL; Zhou HH J Pharmacol Exp Ther; 2000 Nov; 295(2):844-51. PubMed ID: 11046127 [TBL] [Abstract][Full Text] [Related]
10. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Yu KS; Yim DS; Cho JY; Park SS; Park JY; Lee KH; Jang IJ; Yi SY; Bae KS; Shin SG Clin Pharmacol Ther; 2001 Apr; 69(4):266-73. PubMed ID: 11309556 [TBL] [Abstract][Full Text] [Related]
11. Enhanced effect of triazolam with diltiazem. Kosuge K; Nishimoto M; Kimura M; Umemura K; Nakashima M; Ohashi K Br J Clin Pharmacol; 1997 Apr; 43(4):367-72. PubMed ID: 9146848 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Desta Z; Zhao X; Shin JG; Flockhart DA Clin Pharmacokinet; 2002; 41(12):913-58. PubMed ID: 12222994 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation. Ishizaki T; Chiba K; Manabe K; Koyama E; Hayashi M; Yasuda S; Horai Y; Tomono Y; Yamato C; Toyoki T Clin Pharmacol Ther; 1995 Aug; 58(2):155-64. PubMed ID: 7648765 [TBL] [Abstract][Full Text] [Related]
14. Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve. Niioka T; Uno T; Yasui-Furukori N; Shimizu M; Sugawara K; Tateishi T Eur J Clin Pharmacol; 2006 Oct; 62(10):855-61. PubMed ID: 16915367 [TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetics of zotepine and various factors affecting that of zotepine]. Tanaka O Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Apr; 16(2):49-52. PubMed ID: 8905790 [TBL] [Abstract][Full Text] [Related]
16. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Cho JY; Yu KS; Jang IJ; Yang BH; Shin SG; Yim DS Br J Clin Pharmacol; 2002 Apr; 53(4):393-7. PubMed ID: 11966672 [TBL] [Abstract][Full Text] [Related]
17. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Wang LS; Zhou G; Zhu B; Wu J; Wang JG; Abd El-Aty AM; Li T; Liu J; Yang TL; Wang D; Zhong XY; Zhou HH Clin Pharmacol Ther; 2004 Mar; 75(3):191-7. PubMed ID: 15001970 [TBL] [Abstract][Full Text] [Related]
18. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376 [TBL] [Abstract][Full Text] [Related]
19. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. Schmider J; Greenblatt DJ; von Moltke LL; Shader RI J Clin Psychopharmacol; 1996 Aug; 16(4):267-72. PubMed ID: 8835701 [No Abstract] [Full Text] [Related]
20. Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Gardner MJ; Baris BA; Wilner KD; Preskorn SH Clin Pharmacokinet; 1997; 32 Suppl 1():43-9. PubMed ID: 9068935 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]